Ashish Saharia, MD
Surgery · Sugar Land, TXNPI 1821241571
Payments from drug & device makers
Across 271 payments — averaging $1719.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Transmedics, Inc.$405K
- Takeda Pharmaceuticals U.S.A., Inc.$30K
- Paragonix Technologies, Inc.$13K
- Intuitive Surgical$8K
- Shire North American Group Inc$3K
- Boston Scientific$2K
- plus $5K from 36 others
What the payments were for
- Travel & lodging$9376%
- Food & beverage$6,79243%
- Education$8,00051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,000
- TheraSphere Y90 Glass Microspheres 10 GBq$2,358
- Reltone 200 Mg$171
- Reltone 400 Mg$171
- HemoBlast Bellows$168
- LIVTENCITY$125
- TERLIVAZ$122
- uTASWako AFP-L3$121
How this compares
$465,912 in reported general payments places this provider in the 95th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 149 | $106,178 |
| Everolimus | 39 | $99,547 |
| Tacrolimus | 360 | $58,254 |
| Ursodiol | 300 | $41,554 |
| Valganciclovir Hcl | 84 | $27,299 |
| VemlidyTenofovir Alafenamide | 15 | $23,380 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $22,412 |
| ZarxioFilgrastim-Sndz | 25 | $20,020 |
| Mycophenolate Mofetil | 160 | $19,834 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $18,883 |
| Mycophenolic AcidMycophenolate Sodium | 41 | $13,807 |
| EliquisApixaban | 15 | $13,213 |
| Entecavir | 43 | $11,165 |
| Cyclosporine ModifiedCyclosporine, Modified | 42 | $7,178 |
| Tenofovir Disoproxil Fumarate | 52 | $6,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $278 | $23,38015 claims |
| AstraZenecaLokelma | $184 | $22,41225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,830 surgery providers in Texas.
Other surgery in Sugar Land
- Funda MericHouston$20.6M
- Michael HarkinsTomball$2.7M
- Lloyd StegemannCorpus Christi$1.9M
- Douglas StoddardAustin$1.4M
- Erik WilsonBellaire$1.2M
- Thomas SerenaShenandoah$1.2M
- Steven FassAustin$989K
- Vineet ChoudhryAustin$924K
- Isidoro WienerHouston$850K
- Andy HawthorneRound Rock$843K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.